Krystal Biotech to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
September 07, 2021 16:31 ET
|
Krystal Biotech, Inc.
PITTSBURGH, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced it will be featured as a...
Krystal Biotech Reports Second Quarter 2021 Financial Results and Provides Update on Operational Progress
August 09, 2021 08:00 ET
|
Krystal Biotech, Inc.
Top-line data from the pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (“DEB”) on track for 4Q21Initiation of Phase 1 study of inhaled KB407 for the treatment of cystic fibrosis...
Krystal Biotech Provides Update on the Clinical Trial Evaluating Topical KB105 for the Treatment of TGM-1 Associated Ichthyosis
July 01, 2021 16:15 ET
|
Krystal Biotech, Inc.
- New data include update from the fourth patient treated in the Phase 1/2 trial - Repeat topical KB105 dosing continues to be well tolerated with no adverse events or evidence of immune response ...
Krystal Biotech to Participate in Upcoming Investor Conferences
June 03, 2021 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, June 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced participation in two...
Krystal Biotech Reports First Quarter 2021 Financial Results and Provides Update on Operational Progress
May 10, 2021 08:00 ET
|
Krystal Biotech, Inc.
Completed enrollment in pivotal GEM-3 study of B-VEC in dystrophic epidermolysis bullosa (DEB) Strong balance sheet with March 31, 2021 cash, cash equivalents and short-term investments of $403.4...
Krystal Biotech Appoints Andy Orth as Chief Commercial Officer
May 03, 2021 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, May 03, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, announced today the appointment of Andy Orth...
Krystal Biotech Announces Virtual Presentation of Data from its Vector-Encoded-Antibody Platform at ASGCT
April 27, 2021 16:35 ET
|
Krystal Biotech, Inc.
PITTSBURGH, April 27, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that it will present...
Krystal Biotech Provides Update on Pivotal GEM-3 Study of B-VEC for DEB
April 26, 2021 16:05 ET
|
Krystal Biotech, Inc.
PITTSBURGH, April 26, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced modifications to the...
Krystal Biotech Provides Updates from its Rare Genetic Lung Disease Pipeline
April 19, 2021 08:00 ET
|
Krystal Biotech, Inc.
New preclinical data from GLP toxicology and biodistribution study demonstrates in vivo safety of KB407 for cystic fibrosisCompany expands rare genetic lung disease pipeline with KB408 for the...
Krystal Biotech Announces Completion of Patient Enrollment in the GEM-3 Pivotal Trial of B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
March 30, 2021 08:00 ET
|
Krystal Biotech, Inc.
PITTSBURGH, March 30, 2021 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapies for rare diseases, today announced that enrollment is complete...